Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONFERENCE CALL WILL BE HELD TODAY, THURSDAY, NOVEMBER 13 AT 10:00 AM ET WOBURN, MA, NOV. 13, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ:BFRI) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT) IN DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND PROVIDED A BUSINESS UPDATE. FINANCIAL HIGHLIGHTS REVENUES FOR THE FIRST NINE MONTHS OF 2025 WERE STABLE WITH $24.6 MILLION COMPARED TO $24.8 MILLION FOR THE SAME PERIOD IN 2024 THE 2025 RESULT WAS ACHIEVED WITHOUT THE BUY-IN EFFECTS FROM A PRICE INCREASE IN 3Q25 REVENUES WERE $7.0 MILLION, LAGGING BEHIND THE $9.0 MILLION IN 3Q24 DUE TO ADVANCED PURCHASES AHEAD OF THE COMPANY'S OCTOBER 2024 PRICE INCREASE 4Q25 REVENUES ARE EXPECTED TO COMPENSATE FOR THIS EFFECT AND RESULT IN SUBSTANTIAL ANNUAL YEAR-OVER-YEAR GROWTH OPERATING EXPENSES DECREASED 5% YEAR OVER YEAR IN 3Q25 COMPARED TO 3Q24 CASH BALANCE WAS $3.4 MILLION AS OF SEPTEMBER 30, 2025 RECENT OPERATIONAL HIGHLIGHTS CLOSED THE PURCHASE OF ALL AMELUZ AND RHODOLED US ASSETS FROM BIOFRONTERA AG.

BIOFRONTERA INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WOBURN, MASS., NOV. 07, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT IT HAS DIVESTED ITS US LICENSE FOR XEPI (OZENOXACIN) CREAM, 1% TO PELTHOS THERAPEUTICS INC. BIOFRONTERA RECEIVED $3 MILLION AT CLOSING, AND IS TO RECEIVE AN ADDITIONAL $1 MILLION UPON AVAILABILITY OF COMMERCIAL PRODUCT, AND UP TO $6 MILLION IN MILESTONE PAYMENTS, WITH $3 MILLION EACH TIED TO ACHIEVING $10 MILLION AND $15 MILLION IN ANNUAL NET REVENUES FOR XEPI, RESPECTIVELY, WITHIN THE U.S., PUERTO RICO AND THE U.S. VIRGIN ISLANDS.

BIOFRONTERA INC. ANNOUNCES SALE OF LICENSE TO XEPI ANTIBIOTIC CREAM TO PELTHOS THERAPEUTICS INC. FOR UP TO $10M

WOBURN, MASS., NOV. 06, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AFTER THE CLOSE OF THE U.S. FINANCIAL MARKETS ON WEDNESDAY, NOVEMBER 12, 2025. THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, NOVEMBER 13 AT 10:00AM EASTERN TIME TO DISCUSS THOSE RESULTS, PROVIDE A BUSINESS UPDATE AND ANSWER QUESTIONS.

BIOFRONTERA INC. TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 12, 2025 AND HOST A CONFERENCE CALL ON NOVEMBER 13, 2025

WOBURN, MASS., OCT. 23, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE CLOSING OF ITS RESTRUCTURING AND ASSET PURCHASE AGREEMENT WITH ITS FORMER PARENT COMPANY, BIOFRONTERA AG. UNDER THE TRANSACTION, BIOFRONTERA INC. HAS ACQUIRED ALL U.S. ASSETS AND RIGHTS RELATED TO AMELUZ AND RHODOLED, INCLUDING THE NEW DRUG APPLICATION (NDA), INVESTIGATIONAL NEW DRUG APPLICATION (IND), MANUFACTURING RIGHTS AND CONTRACTS, ALL INTELLECTUAL PROPERTY, AND RELATED PERSONNEL.

BIOFRONTERA INC. CLOSES PURCHASE OF ALL AMELUZ AND RHODOLED US ASSETS FROM BIOFRONTERA AG

WOBURN, MA, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC., (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A WEBCAST PRESENTATION AND HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE, TAKING PLACE VIRTUALLY ON TUESDAY, SEPTEMBER 30, 2025.

BIOFRONTERA INC. TO PARTICIPATE IN THE LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE ON SEPTEMBER 30, 2025

WOBURN, MASS., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), HAS ENGAGED LYTHAM PARTNERS TO LEAD A STRATEGIC INVESTOR RELATIONS AND SHAREHOLDER COMMUNICATION PROGRAM.

Biofrontera Inc.

BFRI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biofrontera Inc.

BFRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BFRI